EQTEC (AIM: EQT) said Haverton WTV, a wholly owned subsidiary of EQTEC, and Scott Bros. Enterprises Limited ("Scott Bros") have together signed a conditional land purchase agreement relation to the land on which the proposed up to 25 MWe Billingham waste gasification and power plant at Haverton Hill, Billingham, UK, will be constructed.
Shield Therapeutics (STX), the commercial stage pharmaceutical company, has announced a proposed fundraising to raise up to £25.0 million at a price of 30p a share as well as an open offer for shareholders to raise up to £4.2 million. The proceeds will be used to advance the self-commercialisation of its iron deficiency treatment Accrufer® in the US.
Silence Therapeutics (SLN), the drug discovery group focused on therapeutics for diseases with significant unmet need, is set to receive a $2m milestone payment after initiating work on a third target being explored under its ongoing RNAi research collaboration with Mallinckrodt for the treatment of complement pathway-mediated diseases.
Scancell Holdings (SCLP), the developer of novel immunotherapies for the treatment of cancer and infectious disease runs through their latest investor presentation and answers investor questions including those on their COVID vaccine candidate and expected milestones for 2021.
Escape Hunt, which operates within the escape rooms sector, said it has exchanged contracts to acquire its French master franchise partner, BGP Escape, with the acquisition expected to be completed on or before 15 March 2021. In a separate trading update, the Group said that it has seen ‘modest improvement’ and that it expects be in ‘a strong position to benefit from a resumption of activity once lockdown restrictions are lifted.’